In conclusion, the results of this study provide evidence that fenofibrate can regulate visceral obesity and NAFLD, partly through visceral adipose tissue PPARα activation, in obese OVX mice. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.